Human prostatic acid phosphatase: Structure, function and regulation

International Journal of Molecular Sciences

Volumn 14, Issue 5, 2013, Pages 10438-10464

  Muniyan, Sakthivel ^a   Chaturvedi, Nagendra K ^a   Dwyer, Jennifer G ^a   LaGrange, Chad A ^a   Chaney, William G ^a,b   Lin, Ming Fong ^a,b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Epigenetic regulation; ErbB 2; Immunotherapy; Prostate cancer; Prostatic acid phosphatase; Protein tyrosine phosphatase; Tumor suppressor

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SIPULEUCEL T; ACID PHOSPHATASE;

ALLOSTERISM; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME REGULATION; ENZYME STRUCTURE; EPIGENETICS; GENE; GENE EXPRESSION REGULATION; HORMONE SENSITIVITY; HUMAN; NONHUMAN; PROSTATIC ACID PHOSPHATASE GENE; PROTEIN EXPRESSION; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TISSUE DISTRIBUTION; TRANSCRIPTION REGULATION; AMINO ACID SEQUENCE; BIOLOGICAL MODEL; ENZYMOLOGY; GENETICS; MALE; METABOLISM; MOLECULAR GENETICS; PROSTATE TUMOR;

ACID PHOSPHATASE; AMINO ACID SEQUENCE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION;

EID: 84878230623     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140510438     Document Type: Review

References (171)

1. Gutman, E.B.; Sproul, E.E.; Gutman, A.B. Significance of increased phosphatase activity at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am. J. Cancer 1936, 28, 485-495.
2. Huggins, C.; Hodges, C.V. Studies on prostatic cancer: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941, 1, 293-297.
3. Papsidero, L.D.; Wojcieszyn, J.W.; Horoszewicz, J.S.; Leong, S.S.; Murphy, G.P.; Chu, T.M. Isolation of prostatic acid phosphatase-binding immunoglobulin G from human sera and its potential for use as a tumor-localizing reagent. Cancer Res. 1980, 40, 3032-3035.
4. Wang, M.C.; Papsidero, L.D.; Kuriyama, M.; Valenzuela, L.A.; Murphy, G.P.; Chu, T.M. Prostate antigen: A new potential marker for prostatic cancer. Prostate 1981, 2, 89-96.
5. Chu, T.M.; Lin, M.F. PSA and acid phosphatase in the diagnosis of prostate cancer. J. Clin. Lig. Assay 1998, 21, 24-34.
6. Zagars, G.K.; von Eschenbach, A.C.; Ayala, A.G. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer 1993, 72, 1709-1725.
7. Fowler, J.E., Jr.; Pandey, P.; Seaver, L.E.; Feliz, T.P.; Braswell, N.T. Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. J. Urol. 1995, 153, 1860-1865.
8. Zagars, G.K.; Pollack, A.; von Eschenbach, A.C. Serum testosterone-A significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 1997, 49, 327-334.
9. Taira, A.; Merrick, G.; Wallner, K.; Dattoli, M. Reviving the acid phosphatase test for prostate cancer. Oncology (Williston Park) 2007, 21, 1003-1010.
10. Han, M.; Partin, A.W.; Pound, C.R.; Epstein, J.I.; Walsh, P.C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol. Clin. North Am. 2001, 28, 555-565.
11. Gyorkey, F. Some aspects of cancer of the prostate gland. Meth. Cancer Res. 1973, 10, 279-368.
12. Yam, L.T. Clinical significance of the human acid phosphatases: A review. Am. J. Med. 1974, 56, 604-616.
13. Meng, T.C.; Lin, M.F. Tyrosine phosphorylation of c-ErbB-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells. J. Biol. Chem. 1998, 273, 22096-22104.
14. Veeramani, S.; Yuan, T.C.; Chen, S.J.; Lin, F.F.; Petersen, J.E.; Shaheduzzaman, S.; Srivastava, S.; MacDonald, R.G.; Lin, M.F. Cellular prostatic acid phosphatase: A protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr. Relat. Cancer 2005, 12, 805-822.
15. Chuang, T.D.; Chen, S.J.; Lin, F.F.; Veeramani, S.; Kumar, S.; Batra, S.K.; Tu, Y.; Lin, M.F. Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth. J. Biol. Chem. 2010, 285, 23598-23606.
16. Veeramani, S.; Lee, M.S.; Lin, M.F. Revisiting histidine-dependent acid phosphatases: A distinct group of tyrosine phosphatases. Trends Biochem. Sci. 2009, 34, 273-278.
17. Martland, M.; Hansman, F.S.; Robison, R. The phosphoric-esterase of blood. Biochem. J. 1924, 18, 1152-1160.
18. Moss, D.W.; Raymond, F.D.; Wile, D.B. Clinical and biological aspects of acid phosphatase. Crit. Rev. Clin. Lab. Sci. 1995, 32, 431-467.
19. Yousef, G.M.; Diamandis, M.; Jung, K.; Diamandis, E.P. Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis. Genomics 2001, 74, 385-395.
20. Derechin, M.; Ostrowski, W.; Galka, M.; Barnard, E.A. Acid phosphomonoesterase of human prostate: Molecular weight, dissociation and chemical composition. Biochim. Biophys. Acta 1971, 250, 143-154.
21. Luchter-Wasyl, E.; Ostrowski, W. Subunit structure of human prostatic acid phosphatase. Biochim. Biophys. Acta 1974, 365, 349-359.
22. Lee, C.L.; Li, S.S.; Chu, T.M. Immunologically reactive tryptic fragments of human prostatic acid phosphatase. Biochem. J. 1984, 223, 871-877.
23. Hakalahti, L.; Vihko, P. Purification of monoclonal antibodies raised against prostate-specific acid phosphatase for use in vivo in radioimaging of prostatic cancer. J. Immunol. Methods 1989, 117, 131-136.
24. Vihko, P. Human prostatic acid phosphatases: Purification of a minor enzyme and comparisons of the enzymes. Invest. Urol. 1979, 16, 349-352.
25. Lad, P.M.; Learn, D.B.; Cooper, J.F.; Reisinger, D.M. Distribution of prostatic acid phosphatase isoenzymes in normal and cancerous states. Clin. Chim. Acta 1984, 141, 51-65.
26. Boissonneault, M.; Chapdelaine, A.; Chevalier, S. The enhancement by pervanadate of tyrosine phosphorylation on prostatic proteins occurs through the inhibition of membrane-associated tyrosine phosphatases. Dev. Mol. Cell. Biochem. 1996, 153, 139-144.
27. White, K.Y.; Rodemich, L.; Nyalwidhe, J.O.; Comunale, M.A.; Clements, M.A.; Lance, R.S.; Schellhammer, P.F.; Mehta, A.S.; Semmes, O.J.; Drake, R.R. Glycomic characterization of prostatespecific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. J. Proteome Res. 2009, 8, 620-630.
28. Xia, X.Z.; Lin, M.F. University of Southern California, Los Angeles, CA, USA. Unpublished work, 1993.
29. Vihko, P. Characterization of the principal human prostatic acid phosphatase isoenzyme, purified by affinity chromatography and isoelectric focusing. Part II. Clin Chem. 1978, 24, 1783-1787.
30. Quintero, I.B.; Araujo, C.L.; Pulkka, A.E.; Wirkkala, R.S.; Herrala, A.M.; Eskelinen, E.L.; Jokitalo, E.; Hellstrom, P.A.; Tuominen, H.J.; Hirvikoski, P.P, et al. Prostatic acid phosphatase is not a prostate specific target. Cancer Res. 2007, 67, 6549-6554.
31. Mori, K.; Wakasugi, C. Immunocytochemical demonstration of prostatic acid phosphatase: Different secretion kinetics between normal, hyperplastic and neoplastic prostates. J. Urol. 1985, 133, 877-883.
32. Hoyhtya, M.; Vihko, P.; Vuolas, L.; Tryggvason, K.; Vihko, R. High-affinity monoclonal antibodies specific for human prostatic acid phosphatase. Clin. Chem. 1987, 33, 103-107.
33. Lilja, H.; Abrahamsson, P.A. Three predominant proteins secreted by the human prostate gland. Prostate 1988, 12, 29-38.
34. Li, C.Y.; Lam, W.K.; Yam, L.T. Immunohistochemical diagnosis of prostatic cancer with metastasis. Cancer 1980, 46, 706-712.
35. Shaw, L.M.; Yang, N.; Brooks, J.J.; Neat, M.; Marsh, E.; Seamonds, B. Immunochemical evaluation of the organ specificity of prostatic acid phosphatase. Clin. Chem. 1981, 27, 1505-1512.
36. Yam, L.T.; Janckila, A.J.; Li, C.Y.; Lam, W.K. Presence of "prostatic" acid phosphatase in human neutrophils. Invest. Urol. 1981, 19, 34-38.
37. Waheed, A.; van Etten, R.L.; Gieselmann, V.; von Figura, K. Immunological characterization of human acid phosphatase gene products. Biochem. Genet. 1985, 23, 309-319.
38. Kamoshida, S.; Tsutsumi, Y. Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: Distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum. Pathol. 1990, 21, 1108-1111.
39. Drenckhahn, D.; Waheed, A.; van Etten, R. Demonstration of prostatic-type acid phosphatase in non-lysosomal granules in the crypt epithelium of the human duodenum. Histochemistry 1987, 88, 47-52.
40. Choe, B.K.; Pontes, E.J.; Rose, N.R.; Henderson, M.D. Expression of human prostatic acid phosphatase in a pancreatic islet cell carcinoma. Invest. Urol. 1978, 15, 312-318.
41. Lam, K.W.; Li, C.Y.; Yam, L.T.; Sun, T.; Lee, G.; Ziesmer, S. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate 1989, 15, 13-21.
42. Cunha, A.C.; Weigle, B.; Kiessling, A.; Bachmann, M.; Rieber, E.P. Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett. 2006, 236, 229-238.
43. Graddis, T.J.; McMahan, C.J.; Tamman, J.; Page, K.J.; Trager, J.B. Prostatic acid phosphatase expression in human tissues. Int. J. Clin. Exp. Pathol. 2011, 4, 295-306.
44. Wang, Y.; Harada, M.; Yano, H.; Ogasawara, S.; Takedatsu, H.; Arima, Y.; Matsueda, S.; Yamada, A.; Itoh, K. Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J. Immunother. 2005, 28, 535-541.
45. Goldfarb, D.A.; Stein, B.S.; Shamszadeh, M.; Petersen, R.O. Age-related changes in tissue levels of prostatic acid phosphatase and prostate specific antigen. J. Urol. 1986, 136, 1266-1269.
46. Ronnberg, L.; Vihko, P.; Sajanti, E.; Vihko, R. Clomiphene citrate administration to normogonadotropic subfertile men: Blood hormone changes and activation of acid phosphatase in seminal fluid. Int. J. Androl. 1981, 4, 372-378.
47. Ahmann, F.R.; Schifman, R.B. Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer. J. Urol. 1987, 137, 431-434.
48. Simsek, U.; Kutlu, S.; Yavascaouglu, I.; Oktay, B.; Ozyurt, M. Seasonal variation of prostatic acid phosphate and prostate-specific antigen in patients without prostatic malignancy. Eur. Urol. 1992, 21, 111-114.
49. Robles, J.M.; Morell, A.R.; de Torres, J.A.; Rosello, A.S. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: A comparative study. Int. J. Biol. Markers 1989, 4, 87-94.
50. Abrahamsson, P.A.; Lilja, H.; Falkmer, S.; Wadström, L.B. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 1988, 12, 39-46.
51. Sinha, A.A.; Gleason, D.F.; Wilson, M.J.; Wick, M.R.; Reddy, P.K.; Blackard, C.E. Relationship of prostatic acid phosphatase localization in human prostate by a monoclonal antibody with the Gleason grading system. Prostate 1988, 13, 1-15.
52. Sakai, H.; Shiraishi, K.; Minami, Y.; Yushita, Y.; Kanetake, H.; Saito, Y. Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma. Prostate 1991, 19, 265-272.
53. Ozu, C.; Nakashima, J.; Horiguchi, Y.; Oya, M.; Ohigashi, T.; Murai, M. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int. J. Urol. 2008, 15, 419-422.
54. Clark, N.L.; Swanson, W.J. Pervasive adaptive evolution in primate seminal proteins. PLoS Genet. 2005, 1, e35.
55. ACPP protein [Bos Taurus]. Available online: http://www.ncbi.nlm.nih.gov/protein/AAI46094 (accessed on 28 February 2013).
56. Prostatic acid phosphatase [Mus musculus]. Available online: http://www.ncbi.nlm.nih.gov/protein/ AAF23171.1 (accessed on 28 February 2013).
57. Winqvist, R.; Virkkunen, P.; Grzeschik, K.H.; Vihko, P. Chromosomal localization to 3q21→Qter and two TaqI RFLPs of the human prostate-specific acid phosphatase gene (ACPP). Cytogenet. Cell Genet. 1989, 52, 68-71.
58. Vihko, P.; Virkkunen, P.; Henttu, P.; Roiko, K.; Solin, T, Huhtala, M.L. Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett. 1988, 236, 275-281.
59. Sharief, F.S.; Li, S.S. Structure of human prostatic acid phosphatase gene. Biochem. Biophys. Res. Commun. 1992,184, 1468-1476.
60. Li, S.S.; Sharief, F.S. The prostatic acid phosphatase (ACPP) gene is localized to human chromosome 3q21-q23. Genomics 1993, 17, 765-766.
61. Banas, B.; Blaschke, D.; Fittler, F.; Horz, W. Analysis of the promoter of the human prostatic acid phosphatase gene. Biochim. Biophys. Acta 1994, 1217, 188-194.
62. Solin, T.; Kontturi, M.; Pohlmann, R.; Vihko, P. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): Evaluation by RNA blot analyses. Biochim. Biophys. Acta 1990, 1048, 72-77.
63. Zelivianski, S.; Comeau, D.; Lin, M.F. Cloning and analysis of the promoter activity of the human prostatic acid phosphatase gene. Biochem. Biophys. Res. Comm. 1998, 245, 108-112.
64. Roiko, K.; Janne, O.A.; Vihko, P. Primary structure of rat secretory acid phosphatase and comparison to other acid phosphatases. Gene 1990, 89, 223-229.
65. Porvari, K.; Kurkela, R.; Kivinen, A.; Vihko, P. Differential androgen regulation of rat prostatic acid phosphatase transcripts. Biochem. Biophys. Res. Commun. 1995, 213, 861-868.
66. Geier, C.; von Figura, K.; Pohlmann, R. Structure of the human lysosomal acid phosphatase gene. Eur. J. Biochem. 1989, 183, 611-616.
67. Virkkunen, P.; Hedberg, P.; Palvimo, J.J.; Birr, E.; Porvari, K.; Ruokonen, M.; Taavitsainen, P.; Jänne, O.A.; Vihko, P. Structural comparison of human and rat prostate-specific acid phosphatase genes and their promoters: Identification of putative androgen response elements. Biochem. Biophys. Res. Commun. 1994, 202, 49-57.
68. Sharief, F.S.; Lee, H.; Leuderman, M.M.; Lundwall, A.; Deaven, L.L.; Lee, C.L.; Li, S.S. Human prostatic acid phosphatase: CDNA cloning, gene mapping and protein sequence homology with lysosomal acid phosphatase. Biochem. Biophys. Res. Commun. 1989, 160, 79-86.
69. Schneider, G.; Lindqvist, Y.; Vihko, P. Three-dimensional structure of rat acid phosphatase. EMBO J. 1993, 12, 2609-2615.
70. Peters, C.; Geier, C.; Pohlmann, R.; Waheed, A.; von Figura, K.; Roiko, K.; Virkkunen, P.; Henttu, P.; Vihko, P. High degree of homology between primary structure of human lysosomal acid phosphatase and human prostatic acid phosphatase. Biol. Chem. Hoppe-Seyler 1989, 370, 177-181.
71. Lee, H.; Chu, T.M.; Li, S.S.; Lee, C.L. Homodimer and heterodimer subunits of human prostate acid phosphatase. Biochem. J. 1991, 277, 759-765.
72. Ostrowski, W.S.; Kuciel, R. Human prostatic acid phosphatase: Selected properties and practical applications. Clin. Chim. Acta. 1994, 226, 121-129.
73. Kuciel, R.; Bakalova, A.; Mazurkiewicz, A.; Bilska, A.; Ostrowski, W. Is the subunit of prostatic phosphatase active? Reversible denaturation of prostatic acid phosphatase. Biochem. Int. 1990, 22, 329-334.
74. Van Etten, R.L.; Davidson, R.; Stevis, P.E.; MacArthur, H.; Moore, D.L. Covalent structure, disulfide bonding, and identification of reactive surface and active site residues of human prostatic acid phosphatase. J. Biol. Chem. 1991, 266, 2313-2319.
75. Ostanin, K.; Saeed, A.; van Etten, R.L. Heterologous expression of human prostatic acid phosphatase and site-directed mutagenesis of the enzyme active site. J. Biol. Chem. 1994, 269, 8971-8978.
76. Jakob, C.G.; Lewinski, K.; Kuciel, R.; Ostrowski, W.; Lebioda, L. Crystal structure of human prostatic acid phosphatase. Prostate 2000, 42, 211-218.
77. Murzin, A.G.; Brenner, S.E.; Hubbard, T.; Chothia, C. SCOP: A structural classification of proteins database for the investigation ofsequences and structures. J. Mol. Biol. 1995, 247, 536-540.
78. Ortlund, E.; LaCount, M.W.; Lebioda, L. Crystal structures of human prostatic acid phosphatase in complex with a phosphate ion and a-benzylaminobenzylphosphonic acid update the mechanistic picture and offer new insights into inhibitor design. Biochemistry 2003, 42, 383-389.
79. Van Etten, R.L. Human prostatic acid phosphatase: A histidine phosphatase. Ann. N.Y. Acad. Sci. 1982, 390, 27-51.
80. Sharma, S.; Rauk, A.; Juffer, A.H. A DFT study on the formation of a phosphohistidine intermediate in prostatic acid phosphatase. J. Am. Chem. Soc. 2008, 130, 9708-9716.
81. Chu, T.M.; Wang, M.C.; Merrin, C.; Valenzuela, L.; Murphy, G.P. Isoenzymes of human prostate acid phosphatase. Oncology 1978, 35, 198-200.
82. Lin, M.F.; Lee, C.L.; Li, S.S.; Chu, T.M. Purification and characterization of a new human prostatic acid phosphatase isoenzyme. Biochemistry 1983, 22, 1055-1062.
83. Lam, K.W.; Lee, P.; Eastlund, T.; Yam, L.T. Antigenic and molecular relationship of human prostatic acid phosphatase isoenzymes. Invest. Urol. 1980, 18, 209-211.
84. Moss, D.W. Multiple forms of acid and alkaline phosphatases: Genetics, expression and tissue-specific modification. Clin. Chim. Acta 1986, 161, 123-135.
85. Luchter-Wasylewska, E.; Wasylewski, M.; Röhm, K.H. Concentration-dependent dissociation/ association of human prostatic acid phosphatase. J. Protein Chem. 2003, 22, 243-247.
86. Porvari, K.S.; Herrala, A.M.; Kurkela, R.M.; Taavitsainen, P.A.; Lindqvist, Y.; Schneider, G.; Vihko, P.T. Site-directed mutagenesis of prostatic acid phosphatase. Catalytically important aspartic acid 258, substrate specificity, and oligomerization. J. Biol. Chem. 1994, 269, 22642-22646.
87. Reif, A.E.; Schlesinger, R.M.; Fish, C.A.; Robinson, C.M. Acid phosphatase isozymes in cancer of the prostate. Cancer 1973, 31, 689-699.
88. Hakalahti, L.; Vihko, P.; Henttu, P.; Autio-Harmainen, H.; Soini, Y.; Vihko, R. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int. J. Cancer 1993, 55, 590-597.
89. Lin, M.F.; Lee, M.S.; Zhou, X.W.; Andressen, J.C.; Meng, T.C.; Johansson, S.L.; West, W.W.; Taylor, R.J.; Anderson, J.R.; Lin, F.F. Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. J. Urol. 2001, 166, 1943-1950.
90. Hassan, M.I.; Aijaz, A.; Ahmad, F. Structural and functional analysis of human prostatic acid phosphatase. Expert Rev. Anticancer Ther. 2010, 10, 1055-1068.
91. Lin, M.F.; DaVolio, J.; Garcia-Arenas, R. Expression of human prostatic acid phosphatase activity and the growth of prostate carcinoma cells. Cancer Res. 1992, 52, 4600-4607.
92. Lin, M.F.; Meng, T.C.; Rao, P.S.; Chang, C.; Schonthal, A.H.; Lin, F.F. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J. Biol. Chem. 1998, 273, 5939-5947.
93. Igawa, T.; Lin, F.F.; Lee, M.S.; Karan, D.; Batra, S.K.; Lin, M.F. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002, 50, 222-35.
94. Yuan, T.C.; Lin, F.F.; Veeramani, S.; Chen, S.J.; Earp H.S, Lin, M.F. ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor-positive human prostate cancer cells. Oncogene 2007, 26, 7552-7559.
95. Lin, M.F.; Garcia-Arenas, R.; Xia, X.Z.; Biela, B.; Lin, F.F. The cellular level of prostatic acid phosphatase and the growth of human prostate carcinoma cells. Differentiation 1994, 57, 143-149.
96. Igawa, T.; Lin, F.F.; Rao, P.; Lin, M.F. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase. Prostate 2003, 55, 247-258.
97. Stewart, L.V.; Lyles, B.; Lin, MF.; Weigel, N.L. Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J. Steroid Biochem. Mol. Biol. 2005, 97, 37-46.
98. Coffey, D.S.; Pienta, K.J. New concepts in studying the control of normal and cancer growth of the prostate. Prog. Clin. Biol. Res. 1987, 239, 1-73.
99. Saha, A.; Basu, J.; Bhattacharyya, A.K. Seminal acid phosphatase from normal, oligospermic, vasectomized, and azoospermic men. Int. J. Fertil. 1981, 26, 124-127.
100. Singh, G.; Adaikan, P.G.; Ng, Y.K. Is seminal prostatic acid phosphatase a reliable marker for male infertility? Singapore Med. J. 1996, 37, 598-599.
101. Münch, J.; Rücker, E.; Ständker, L.; Adermann, K.; Goffinet, C.; Schindler, M.; Wildum, S.; Chinnadurai, R.; Rajan, D.; Specht, A.; et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007, 131, 1059-1071.
102. Olsen, J.S.; DiMaio, J.T.; Doran, T.M.; Brown, C.; Nilsson, B.L.; Dewhurst, S. Seminal plasma accelerates semen-derived enhancer of viral infection (SEVI) fibril formation by the prostatic acid phosphatase (PAP248-286) peptide. J. Biol. Chem. 2012, 287, 11842-11849.
103. Hunter, T.; Cooper, J.A. Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells. Cell 1981, 24, 741-752.
104. Monget, P.; Pisselet, C.; Monniaux, D. Expression of insulin-like growth factor binding protein-5 by ovine granulosa cells is regulated by cell density and programmed cell death in vitro. J. Cell Physiol. 1998, 177, 13-25.
105. Pfeiffer, D.; Kimmig, R.; Herrmann, J.; Ruge, M.; Fisseler-Eckhoff, A.; Scheidel, P.; Jensen, A.; Schatz, H.; Pfeiffer, A. Epidermal-growth-factor receptor correlates negatively with cell density in cervical squamous epithelium and is down-regulated in cancers of the human uterus. Int. J. Cancer 1998, 79, 49-55.
106. Chevalier, S.; Bleau, G.; Roberts, K.D.; Chapdelaine, A. Proliferation and differentiation of canine prostatic epithelial cells in culture. Mol. Cell. Endocrinol. 1981, 24, 195-208.
107. Dionne, F.T.; Chevalier, S.; Bleau, G.; Roberts, K.D.; Chapdelaine, A. Induction of acid phosphatase synthesis in canine prostatic epithelial cells in vitro. Mol. Cell. Endocrinol. 1983, 33, 113-126.
108. Lin, M.F.; Garcia-Arenas, R.; Kawachi, M.; Lin, F.F. Regulation of the expression of prostatic acid phosphatase in LNCaP human prostate carcinoma cells. Cell. Mol. Biol. Res. 1993, 39, 739-750.
109. Lin, M.F.; Garcia-Arenas, R. Effect of cell density on androgen regulation of the mRNA level of human prostatic acid phosphatase. Mol. Cell. Endocrinol. 1994, 99, R21-24.
110. Lin, M.F.; Garcia-Arenas, R.; Chao, Y.C.; Lai, M.M.; Patel, P.C.; Xia, X.Z. Regulation of prostatic acid phosphatase expression and secretion by androgen in LNCaP human prostate carcinoma cells. Arch. Biochem. Biophy. 1993, 300, 384-390.
111. Shan, J.D.; Porvari, K.; Ruokonen, M.; Karhu, A.; Launonen, V.; Hedberg, P.; Oikarinen, J.; Vihko, P. Steroid-involved transcriptional regulation of human genes encoding prostatic acid phosphatase, prostate-specific antigen, and prostate-specific glandular kallikrein. Endocrinology 1997, 138, 3764-3770.
112. Zelivianski, S.; Larson, C.; Seberger, J.; Taylor, R.; Lin, M.F. Expression of human prostatic acid phosphatase gene is regulated by upstream negative and positive elements. Biochim. Biophys. Acta 2000, 1491, 123-132.
113. Sporn, M.B.; Roberts, A.B.; Wakefield, L.M.; Assoian, R.K. Transforming growth factor-beta: Biological function and chemical structure. Science 1986, 233, 532-534.
114. Martikainen, P.; Kyprianou, N.; Isaacs, J.T. Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology 1990, 127, 2963-2968.
115. Henttu, P.; Vihko, P. Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP. Cancer Res. 1993, 53, 1051-1058.
116. Horoszewicz, J.S.; Leong, S.S.; Kawinski, E.; Karr, J.P.; Rosenthal, H.; Chu, T.M.; Mirand, E.A.; Murphy, G.P. LNCaP model of human prostatic carcinoma. Cancer Res. 1983, 43, 1809-1818.
117. Lin, M.F.; Lee, M.S.; Garcia-Arenas, R.; Lin, F.F. Differential responsiveness of prostatic acid phosphatase and prostate-specific antigen mRNA to androgen in prostate cancer cells. Cell Biol. Int. 2000, 24, 681-689.
118. Henttu, P.; Vihko, P. Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LNCaP cell line. J. Steroid Biochem. Mol. Biol. 1992, 41, 349-360.
119. Lin, M.F.; Zhang, X.Q.; Dean, J.; Lin, F.F. Protein kinase C pathway is involved in regulating the secretion of prostatic acid phosphatase in human prostate cancer cells. Cell Biol. Int. 2001, 25, 1139-1148.
120. Andrews, P.E.; Young, C.Y.; Montgomery, B.T.; Tindall, D.J. Tumor-promoting phorbol ester down-regulates the androgen induction of prostate-specific antigen in a human prostatic adenocarcinoma cell line. Cancer Res. 1992, 52, 1525-1529.
121. Johnson, J.L.; Ellis, B.A.; Noack, D.; Seabra, M.C.; Catz, S.D. The Rab27a-binding protein, JFC1, regulates androgen-dependent secretion of prostate-specific antigen and prostatic-specific acid phosphatase. Biochem. J. 2005, 391, 699-710.
122. Zelivianski, S.; Igawa, T.; Lim, S.; Taylor, R.; Lin, M.F. Identification and characterization of regulatory elements of the human prostatic acid phosphatase promoter. Oncogene 2002, 21, 3696-3705.
123. Zelivianski, S.; Glowacki, R.; Lin, M.F. Transcriptional activation of the human prostatic acid phosphatase gene by NF-kappaB via a novel hexanucleotide-binding site. Nucleic Acids Res. 2004, 32, 3566-3580.
124. Chou, Y.W.; Chaturvedi, N.K.; Ouyang, S.; Lin, F.F.; Kaushik, D.; Wang, J.; Kim, I.; Lin, M.F. Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. Cancer Lett. 2011, 311, 177-186.
125. Riegman, P.H.; Vlietstra, R.J.; van der Korput, J.A.; Brinkmann, A.O.; Trapman, J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol. 1991, 5, 1921-1930.
126. Cleutjens, K.B.; van Eekelen, C.C.; van der Korput, H.A.; Brinkmann, A.O.; Trapman, J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol. Chem. 1996, 271, 6379-6388.
127. Gotoh, A.; Ko, S.C.; Shirakawa, T.; Cheon, J.; Kao, C.; Miyamoto, T.; Gardner, T.A.; Ho, L.J.; Cleutjens, C.B.; Trapman, J, et al. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J. Urol. 1998, 160, 220-229.
128. Miyamoto, S.; Verma, I.M. Rel/NF-kappa B/I kappa B story. Adv. Cancer Res. 1995, 66, 255-292.
129. Perry, A.S. Prostate cancer epigenomics. J. Urol. 2013, 189, 10-11.
130. Albany, C.; Alva, A.S.; Aparicio, A.M.; Singal, R.; Yellapragada, S.; Sonpavde, G.; Hahn, N.M. Epigenetics in prostate cancer. Prostate Cancer 2011, 2011, 580318.
131. Lin, M.F.; Meng, T.C. Tyrosine phosphorylation of a 185 kDa Phosphoprotein (pp185) inversely correlates with the cellular activity of human prostatic acid phosphatase. Biochem. Biophys. Res. Commun. 1996, 226, 206-213.
132. Li, H.C.; Chernoff, J.; Chen, L.B.; Kirschonbaum, A. A phosphotyrosyl-protein phosphatase activity associated with acid phosphatase from human prostate gland. Eur. J. Biochem. 1984, 138, 45-51.
133. Craft, N.; Shostak, Y.; Carey, M.; Sawyers, C.L. Mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 1999, 5, 280-285.
134. Meng, T.C.; Lee, M.S.; Lin, M.F. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene 2000, 19, 2664-2677.
135. Lee, M.S.; Igawa, T.; Yuan, T.C.; Zhang, X.Q.; Lin, F.F.; Lin, M.F. ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells. Oncogene 2003, 22, 781-796.
136. El Sheikh, S.S.; Domin, J.; Abel, P.; Stamp, G.; Lalani, el-N. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 2004, 6, 846-853.
137. Vihko, P.T.; Quintero, I.; Ronka, A.E.; Herrala, A.; Jantti, P.; Porvari, K.; Lindqvist, Y.; Kaija, H.; Pulkka, A.; Vuoristo, J, et al. Prostatic acid phosphatase (PAcP) is PI(3)P-phosphatase and its inactivation leads to change of cell polarity and invasive prostate cancer. Proc. Amer. Assoc. Cancer Res. 2005, 46, 5239.
138. Zylka, M.J.; Sowa, N.A.; Taylor-Blake, B.; Twomey, M.A.; Herrala, A.; Voikar, V.; Vihko, P. Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 2008, 60, 111-122.
139. Loor, R.; Wang, M.C.; Valenzuela, L.; Chu, T.M. Expression of prostatic acid phosphatase in human prostate cancer. Cancer Lett. 1981, 14, 63-69.
140. Alaiya, A.A.; Oppermann, M.; Langridge, J.; Roblick, U.; Egevad, L.; Brindstedt, S.; Hellström, M.; Linder, S.; Bergman, T.; Jörnvall, H.; Auer, G. Identification of proteins in human prostate tumor material by two-dimensional gel electrophoresis and mass spectrometry. Cell. Mol. Life Sci. 2001, 58, 307-311.
141. Yeh, S.; Lin, H.K.; Kang, H.Y.; Thin, T.H.; Lin, M.F, Chang, C. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. PNAS 1999, 96, 5458-5463.
142. Culig, Z.; Hobisch, A.; Cronauer, M.V.; Hittmair, A.; Radmayr, C.; Bartsch, G.; Klocker, H. Activation of the androgen receptor by polypeptide growth factors and cellular regulators. World J. Urol. 1995, 13, 285-289.
143. Grossmann, M.E.; Huang, H.; Tindall, D.J. Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl. Cancer Inst. 2001, 93, 1687-1697.
144. Gioeli, D.; Mandell, J.W.; Petroni, G.R.; Frierson, H.F., Jr.; Weber, M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 1999, 59, 279-284.
145. Zhang, X.Q.; Lee, M.S.; Zelivianski, S.; Lin, M.F. Characterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cells. J. Biol. Chem. 2001, 276, 2544-2550.
146. Wen, Y.; Hu, M.C.; Makino, K.; Spohn, B.; Bartholomeusz, G.; Yan, D.H. Hung, M.C. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000, 60, 6841-6845.
147. Lee, M.S.; Igawa, T.; Lin, M.F. Tyrosine-317 of p52 mediates androgen-stimulated proliferation signals in human prostate cancer cells. Oncogene 2004, 23, 3048-3058.
148. Tan, S.H.; Dagvadorj, A.; Shen, F.; Gu, L.; Liao, Z.; Abdulghani, J.; Zhang, Y.; Gelmann, E.P.; Zellweger, T.; Culig, Z, et al. Transcription factor Stat5 synergizes with androgen receptor in prostatecancer cells. Cancer Res. 2008, 68, 236-248.
149. Coffey, D.S.; Isaacs, J.T. Control of prostate growth. Urology 1981, 17, 17-24.
150. Wang, X.; Yu, J.; Sreekumar, A.; Varambally, S.; Shen, R.; Giacherio, D.; Mehra, R.; Montie, J.E.; Pienta, K.J.; Sanda, M.G, et al. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 2005, 353, 1224-1235.
151. Taylor, B.S.; Varambally, S.; Chinnaiyan, A.M. Differential proteomic alterations between localised and metastatic prostate cancer. Br. J. Cancer 2006, 95, 425-430.
152. Rhodes, D.R.; Barrette, T.R.; Rubin, M.A.; Ghosh, D.; Chinnaiyan, A.M. Meta-analysis of microarrays: Interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002, 62, 4427-4433.
153. Arlen, P.M.; Mohebtash, M.; Madan, R.A.; Gulley, J.L. Promising novel immunotherapies and combinations for prostate cancer. Future Oncol. 2009, 5, 187-196.
154. Drake, C.G.; Jaffee, E.; Pardoll, D.M. Mechanisms of immune evasion by tumors. Adv. Immunol. 2006, 90, 51-81.
155. Fong, L.; Ruegg, C.L.; Brockstedt, D.; Engleman, E.G.; Laus, R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization; implications for immunotherapy of prostate cancer. J. Immunol. 1997, 159, 3113-3117.
156. Johnson, L.E.; Frye, T.P.; Chinnasamy, N.; Chinnasamy, D.; McNeel, D.G. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol. Immunother. 2007, 56, 885-895.
157. Doehn, C. Immunotherapy of prostate cancer. Eur. Urol. 2008, 53, 681-685.
158. Vieweg, J. Immunotherapy for advanced prostate cancer. Rev. Urol. 2007, 9, S29-S38.
159. Drake, C.G. Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 2010, 10, 580-593.
160. McNeel, D.G.; Nguyen, L.D.; Ellis, W.J.; Higano, C.S.; Lange, P.H.; Disis, M.L. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate 2001, 47, 222-229.
161. Small, E.J.; Fratesi, P.; Reese, D.M.; Strang, G.; Laus, R.; Peshwa, M.V.; Valone, F.H. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 2000, 18, 3894-3903.
162. Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B., et al. Impact study investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363, 411-422.
163. Garcia, J.A. Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: An insight for oncologists. Ther. Adv. Med. Oncol. 2011, 3, 101-108.
164. Burch, P.A.; Croghan, G.A.; Gastineau, D.A.; Jones, L.A.; Kaur, J.S.; Kylstra, J.W.; Richardson, R.L.; Valone, F.H.; Vuk-Pavlović, S. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A Phase 2 trial. Prostate 2004, 60, 197-204.
165. Beinart, G.; Rini, B.I.; Weinberg, V.; Small, E.J. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin. Prostate Cancer 2005, 4, 55-60.
166. Rini, B.I.; Weinberg, V.; Fong, L.; Conry, S.; Hershberg, R.M.; Small, E.J. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006, 107, 67-74.
167. Small, E.J.; Higano, C.S.; Kantoff, P.W.; Whitmore, J.B.; Frohlich, M.W.; Petrylak, D.P. Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials. J. Clin. Oncol. 2011, 29, S484.
168. Sheikh, N.A.; Wesley, J.D.; Chadwick, E.; Perdue, N.; de Rosa, C.P. Characterization of antigen-specific T-cell activation and cytokine expression induced by sipuleucel-T. J. Clin. Oncol. 2011, 29, 16-30.
169. McLeod, D.G.; Quinn, D.I.; Whitmore, M.; Tabesh, M. Sipuleucel-T in African Americans: A subgroup analysis of three phase III sipuleucel-T in advanced prostate cancer. J. Clin. Oncol. 2011, 29, e15148.
170. Paller, C.J.; Antonarakis, E.S. Sipuleucel-T for the treatment of metastatic prostate cancer: Promise and challenges. Hum. Vaccin. Immunother. 2012, 8, 509-519.
171. Schellhammer, P.F.; Chodak, G.; Whitmore, J.B.; Sims, R.; Frohlich, M.W.; Kantoff, P.W. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology 2013, in press.